Literature DB >> 11485552

Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.

A M Aslanian1, M S Kilberg.   

Abstract

Childhood acute lymphoblastic leukaemia is treated by combination chemotherapy with a number of drugs, almost always including the enzyme L-asparaginase (ASNase). Although the initial remission rate is quite high, relapse and associated drug resistance remain a problem. In vitro studies have demonstrated an adaptive increase in asparagine synthetase (AS) expression in ASNase-resistant cells, which is believed to permit ASNase-resistant human leukaemia cells to survive in vivo. The present results, obtained with ASNase-sensitive and -resistant human MOLT-4 leukaemia cell lines, illustrate that several other adaptive processes occur to provide sufficient amounts of the AS substrates, aspartate and glutamine, required to support this increased enzymic activity. In both cell populations, aspartate is derived almost exclusively from intracellular sources, whereas the necessary glutamine arises from both intracellular and extracellular sources. Transport of glutamine into ASNase-resistant cells is significantly enhanced compared with the parental cells, whereas amino acid efflux (e.g. asparagine) is reduced. Most of the adaptive change for the amino acid transporters, Systems A, ASC and L, is rapidly (12 h) reversed following ASNase removal. The enzymic activity of glutamine synthetase is also enhanced in ASNase-resistant cells by a post-transcriptional mechanism. The results demonstrate that there are several sites of metabolic adaptation in ASNase-treated leukaemia cells that serve to promote the replenishment of both glutamine and asparagine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11485552      PMCID: PMC1222032          DOI: 10.1042/0264-6021:3580059

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  Cloning of an amino acid transporter with functional characteristics and tissue expression pattern identical to that of system A.

Authors:  M Sugawara; T Nakanishi; Y J Fei; W Huang; M E Ganapathy; F H Leibach; V Ganapathy
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

2.  L-asparaginase in the treatment of neoplastic diseases in children.

Authors:  N Jaffe; D Traggis; L Das; W C Moloney; H W Hann; B S Kim; R Nair
Journal:  Cancer Res       Date:  1971-07       Impact factor: 12.701

3.  E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children.

Authors:  L Tallal; C Tan; H Oettgen; N Wollner; M McCarthy; L Helson; J Burchenal; D Karnofsky; M L Murphy
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

4.  A bicyclic amino acid to improve discriminations among transport systems.

Authors:  H N Christensen; M E Handlogten; I Lam; H S Tager; R Zand
Journal:  J Biol Chem       Date:  1969-03-25       Impact factor: 5.157

5.  Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas.

Authors:  M D Prager; N Bachynsky
Journal:  Biochem Biophys Res Commun       Date:  1968-04-05       Impact factor: 3.575

6.  L-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group.

Authors:  W W Sutow; F Garcia; K A Starling; T E Williams; D M Lane; E A Gehan
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

7.  Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy.

Authors:  H K Miller; J S Salser; M E Balis
Journal:  Cancer Res       Date:  1969-01       Impact factor: 12.701

8.  Inhibition of system A amino acid transport and hepatocyte proliferation following partial hepatectomy in the rat.

Authors:  T L Freeman; H Q Ngo; M E Mailliard
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

9.  A distinct Na+-requiring transport system for alanine, serine, cysteine, and similar amino acids.

Authors:  H N Christensen; M Liang; E G Archer
Journal:  J Biol Chem       Date:  1967-11-25       Impact factor: 5.157

10.  Regulation of glutamine synthetase and glutaminase activities in cultured skeletal muscle cells.

Authors:  R J Smith; S Larson; S E Stred; R P Durschlag
Journal:  J Cell Physiol       Date:  1984-08       Impact factor: 6.384

View more
  31 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

Review 2.  Asparagine synthetase chemotherapy.

Authors:  Nigel G J Richards; Michael S Kilberg
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

Review 3.  Nutritional control of gene expression: how mammalian cells respond to amino acid limitation.

Authors:  M S Kilberg; Y-X Pan; H Chen; V Leung-Pineda
Journal:  Annu Rev Nutr       Date:  2005       Impact factor: 11.848

4.  An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.

Authors:  Jemy A Gutierrez; Yuan-Xiang Pan; Lukasz Koroniak; Jun Hiratake; Michael S Kilberg; Nigel G J Richards
Journal:  Chem Biol       Date:  2006-12

5.  AsnB is involved in natural resistance of Mycobacterium smegmatis to multiple drugs.

Authors:  Huiping Ren; Jun Liu
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 6.  The transcription factor network associated with the amino acid response in mammalian cells.

Authors:  Michael S Kilberg; Mukundh Balasubramanian; Lingchen Fu; Jixiu Shan
Journal:  Adv Nutr       Date:  2012-05-01       Impact factor: 8.701

Review 7.  Asparagine synthetase: Function, structure, and role in disease.

Authors:  Carrie L Lomelino; Jacob T Andring; Robert McKenna; Michael S Kilberg
Journal:  J Biol Chem       Date:  2017-10-30       Impact factor: 5.157

8.  Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines.

Authors:  Jean Hugues Parmentier; Maristella Maggi; Erika Tarasco; Claudia Scotti; Vassilios I Avramis; Steven D Mittelman
Journal:  Leuk Res       Date:  2015-04-22       Impact factor: 3.156

9.  KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia.

Authors:  Fida Khater; Mathieu Lajoie; Sylvie Langlois; Jasmine Healy; Sonia Cellot; Chantal Richer; Patrick Beaulieu; Pascal St-Onge; Virginie Saillour; Mark Minden; Monia Marzouki; Maja Krajinovic; Henrique Bittencourt; Daniel Sinnett
Journal:  Blood       Date:  2017-01-09       Impact factor: 22.113

10.  Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.

Authors:  Ehsan A Ehsanipour; Xia Sheng; James W Behan; Xingchao Wang; Anna Butturini; Vassilios I Avramis; Steven D Mittelman
Journal:  Cancer Res       Date:  2013-04-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.